Old Web
English
Sign In
Acemap
>
authorDetail
>
Firas Almazedi
Firas Almazedi
Medicine
Placebo
Internal medicine
Type 2 diabetes
Gastroenterology
5
Papers
55
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
2021
Antimicrobial Agents and Chemotherapy
Wendy Painter
Wayne Holman
Jim A. Bush
Firas Almazedi
Hamzah Malik
Nicola C.J.E. Eraut
Merribeth J. Morin
Laura J Szewczyk
George R. Painter
Show All
Source
Cite
Save
Citations (41)
Author response for "Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes"
2021
Diabetes, Obesity and Metabolism
Kirsten Dahl
Ashley Brooks
Firas Almazedi
Søren Tetens Hoff
Cristina Boschini
Tine A. Bækdal
Show All
Source
Cite
Save
Citations (0)
Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
2021
Diabetes, Obesity and Metabolism
Kirsten Dahl
Ashley Brooks
Firas Almazedi
Søren Tetens Hoff
Cristina Boschini
Tine A. Bækdal
Show All
Source
Cite
Save
Citations (5)
Human Safety, Tolerability, and Pharmacokinetics of a Novel Broad-Spectrum Oral Antiviral Compound, Molnupiravir, with Activity Against SARS-CoV-2
2020
Wendy Painter
Wayne Holman
James A. Bush
Firas Almazedi
Hamzah Malik
Nicola C.J.E. Eraut
Merribeth J. Morin
Laura J Szewczyk
George R. Painter
Show All
Source
Cite
Save
Citations (9)
The Effectiveness of GLP-1 Analogue Therapy for Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
2009
Firas Almazedi
Show All
Source
Cite
Save
Citations (0)
1